Nε-carboxymethyl lysine (CML) (CML)

Nε-carboxymethyl lysine (CML) is a chemically stable, non-enzymatic modification of protein lysine residues and represents the most prevalent advanced glycation end-product (AGE) in the human body (Ahmed, 2005). It is formed via the Maillard reaction and subsequent oxidative cleavage, making it a definitive biomarker for both glycation and oxidative stress, often referred to as glycoxidation (Dyer et al., 1993). CML accumulates progressively with age and at an accelerated rate in patients with diabetes, where it modifies long-lived extracellular matrix proteins like collagen and elastin (Goldin et al., 2006). The primary pathological mechanism of CML involves its binding to the Receptor for Advanced Glycation End-products (RAGE), which triggers intracellular signaling cascades, such as the activation of NF-κB, leading to chronic inflammation, vascular damage, and tissue fibrosis (Bierhaus et al., 2005). Consequently, CML is a major contributor to the pathogenesis of diabetic nephropathy, atherosclerosis, and neurodegenerative conditions such as Alzheimer's disease (Sasaki et al., 1998). Therapeutic approaches targeting the CML epitope include small-molecule inhibitors of AGE formation, such as pyridoxamine, and experimental monoclonal antibodies designed to selectively clear CML-modified proteins to restore tissue function (Khalifah et al., 1999).

Other names

N(6)-carboxymethyllysine2-amino-6-(carboxymethylamino)hexanoic acidCML-modified proteinN-epsilon-carboxymethyllysine

Inhibition of the Maillard reaction and oxidative cleavage to prevent CML formation; chemical cleavage of established AGE-derived protein cross-links; and immunological targeting for the sequestration and clearance of CML-modified protein epitopes.